Soligenix, Inc. (SNGX)
0.3602
+0.01
(+2.88%)
USD |
NASDAQ |
Oct 22, 11:01
Soligenix EPS Diluted (Quarterly) : -0.1246 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1246 |
| March 31, 2026 | -0.2779 |
| December 31, 2025 | -0.2872 |
| September 30, 2025 | -0.5846 |
| June 30, 2025 | -0.8241 |
| March 31, 2025 | -0.9678 |
| December 31, 2024 | -1.188 |
| September 30, 2024 | -0.7801 |
| June 30, 2024 | -1.306 |
| March 31, 2024 | -2.913 |
| December 31, 2023 | -2.806 |
| September 30, 2023 | -2.563 |
| June 30, 2023 | -3.559 |
| March 31, 2023 | -5.742 |
| December 31, 2022 | -20.83 |
| September 30, 2022 | -18.43 |
| June 30, 2022 | -13.32 |
| March 31, 2022 | -24.32 |
| December 31, 2021 | -26.33 |
| September 30, 2021 | -21.16 |
| June 30, 2021 | -11.36 |
| March 31, 2021 | -15.40 |
| December 31, 2020 | -43.39 |
| September 30, 2020 | -14.53 |
| June 30, 2020 | -24.77 |
| Date | Value |
|---|---|
| March 31, 2020 | -77.74 |
| December 31, 2019 | -33.60 |
| September 30, 2019 | -32.50 |
| June 30, 2019 | -27.64 |
| March 31, 2019 | -21.77 |
| December 31, 2018 | -42.14 |
| September 30, 2018 | -25.54 |
| June 30, 2018 | -42.72 |
| March 31, 2018 | -65.32 |
| December 31, 2017 | -64.80 |
| September 30, 2017 | -40.80 |
| June 30, 2017 | -98.40 |
| March 31, 2017 | -76.80 |
| December 31, 2016 | -33.60 |
| September 30, 2016 | -633.86 |
| June 30, 2016 | -48.00 |
| March 31, 2016 | -144.00 |
| December 31, 2015 | -168.00 |
| September 30, 2015 | -120.00 |
| June 30, 2015 | -360.00 |
| March 31, 2015 | -456.00 |
| December 31, 2014 | -151.73 |
| September 30, 2014 | -504.00 |
| June 30, 2014 | -73.66 |
| March 31, 2014 | -408.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.987M |
| Total Expenses (Quarterly) | 1.987M |
| Enterprise Value | -1.933M |
| Earnings Yield | -353.8% |
| Normalized Earnings Yield | -354.47 |